Related Experiment Video
Updated: Feb 9, 2026

P50 Sensory Gating in Infants
Published on: December 26, 2013
[A case of vaccine-associated paralytic poliomyelitis in an infant]
A S Shishov1, O E Ivanova2, A K Shakaryan1
1Chumakov Federal Scientific Center for Research and Development of Immune-and-biological Products of Russian Academy of Sciences, Moscow, Russia.
Insights
Vaccine-associated paralytic poliomyelitis (VAPP) occurred in a 15-month-old child after receiving an oral poliovirus vaccine (OPV). This case highlights potential immunization defects and unique clinical features of VAPP.
Area of Science:
- Virology
- Immunology
- Pediatrics
Background:
- Poliomyelitis remains a significant public health concern, with vaccine-derived poliovirus posing a risk.
- The oral poliovirus vaccine (OPV) has been instrumental in polio eradication but can rarely lead to vaccine-associated paralytic poliomyelitis (VAPP).
Observation:
- A 15-month-old child received a bivalent (types 1 & 3) oral poliovirus vaccine (OPV) dose.
- The child subsequently developed clinical manifestations consistent with paralytic poliomyelitis.
Findings:
- The patient presented with sudden onset paresis, rapid progression (2-4 days), and persistent residual effects.
- Cerebrospinal fluid (CSF) analysis revealed characteristic protein-cell dissociation.
- Clinical features of VAPP were compared to those caused by wild poliovirus.
Implications:
- The occurrence of VAPP underscores the importance of robust immunization programs and surveillance.
- Understanding VAPP clinical parameters is crucial for accurate diagnosis and management.
- This case highlights the need to address immunization gaps to prevent VAPP.
Aim:
To present the clinical history, vaccination status, features of the clinical picture, composition of the cerebrospinal fluid (CSF), results of laboratory and instrumental examinations of a patient with vaccine-associated paralytic poliomyelitis (VAPP).
Material And Methods:
In 2017, a child, aged 15 month, mistakenly vaccinated with the first dose of bivalent (types 1 & 3) polioviruses oral vaccine (OPV) was followed up.
Results And Conclusion:
Clinical parameters of VAPP in the recipient of OPV are considered. Clinical features of disease caused by wild poliovirus and VAPP are compared. The disease was characterized by sudden onset, recurrence, short (2-4 days) period of progression of paresis, persistent residual effects, CSF protein-cell dissociation. It is emphasized that the occurrence of VAPP cases reflects primarily immunization defects.
Related Concept Videos
Vaccinations
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Drug Dosing: Infants and Children
Theory of Romantic Attachment in Adulthood

